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one. This cellular replacement therapy
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subsequent complications like iron overload.   
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After the  pioneering work by the Se
now widely applied worldwide. Medical therapy of thalassemia is one of 
successes of the medical practice in the last decades. In recent years advances in knowledge of 
iron  overload  patho-physiopathology,  improvement  and  diffusion  of  diagnostic  capability 
together with the development of new effective and 
increase success of medical therapy. Nevertheless situation is dramatically different in non
industrialized countries were the very large majority of patients live today. Transplantation 
technologies have improved sub
likely to be much better today than in the ‘80s. Recent data indicated a probability of overall 
survival and thalassemia free survival of 97% and 89% for patients with no advanced disease 
and of 87% and 80% for patients with advanced disease. 
thalassemia has now been fully established. 
for thalassemia and other hemoblobinopathies. The development of oral chelators
changed this position. However this has not settled the controversy on how this curative but 
potentially  lethal  treatment  stands  in  front  of  medical  therapy  for  adults  and  advanced 
disease  patients.  In  sickle  cell disease    HSC  transplantation  cur
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The basis of allogeneic hemopoietic stem cell (HSC) transplantation in thalassemia 
consists in substituting the ineffective thalassemic erythropoiesis with and allogeneic effective 
cellular replacement therapy is an efficient way to obtain a long lasting, probably 
permanent, clinical effective correction of the anaemia avoiding transfusion requirement and 
omplications like iron overload.   The first HSC transplant for thalassemia was 
performed  in  Seattle  on  Dec  2,  1981.  In  the early  eighties  transplantation  procedure  was 
to very few centres worldwide. Between 17 December 1981 and 31 January 2003, ov
1000  consecutive  patients,  aged  from  1  to  35  years,  underwent  transplantation in  Pesaro. 
After the  pioneering work by the Seattle  and Pesaro groups,  this therapeutic approach is 
now widely applied worldwide. Medical therapy of thalassemia is one of 
successes of the medical practice in the last decades. In recent years advances in knowledge of 
physiopathology,  improvement  and  diffusion  of  diagnostic  capability 
together with the development of new effective and safe oral chelators promise to further 
increase success of medical therapy. Nevertheless situation is dramatically different in non
industrialized countries were the very large majority of patients live today. Transplantation 
technologies have improved substantially during the last years and transplantation outcome is 
likely to be much better today than in the ‘80s. Recent data indicated a probability of overall 
survival and thalassemia free survival of 97% and 89% for patients with no advanced disease 
of 87% and 80% for patients with advanced disease.  Thus the central role of HSC in 
thalassemia has now been fully established. HSC remains the only definitive curative therapy 
for thalassemia and other hemoblobinopathies. The development of oral chelators
changed this position. However this has not settled the controversy on how this curative but 
potentially  lethal  treatment  stands  in  front  of  medical  therapy  for  adults  and  advanced 
sickle  cell disease    HSC  transplantation  currently  is  reserved almost 
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The basis of allogeneic hemopoietic stem cell (HSC) transplantation in thalassemia 
thalassemic erythropoiesis with and allogeneic effective 
is an efficient way to obtain a long lasting, probably 
permanent, clinical effective correction of the anaemia avoiding transfusion requirement and 
The first HSC transplant for thalassemia was 
In  the early  eighties  transplantation  procedure  was 
etween 17 December 1981 and 31 January 2003, over  
1000  consecutive  patients,  aged  from  1  to  35  years,  underwent  transplantation in  Pesaro. 
saro groups,  this therapeutic approach is 
now widely applied worldwide. Medical therapy of thalassemia is one of the most spectacular 
successes of the medical practice in the last decades. In recent years advances in knowledge of 
physiopathology,  improvement  and  diffusion  of  diagnostic  capability 
safe oral chelators promise to further 
increase success of medical therapy. Nevertheless situation is dramatically different in non-
industrialized countries were the very large majority of patients live today. Transplantation 
stantially during the last years and transplantation outcome is 
likely to be much better today than in the ‘80s. Recent data indicated a probability of overall 
survival and thalassemia free survival of 97% and 89% for patients with no advanced disease 
he central role of HSC in 
remains the only definitive curative therapy 
for thalassemia and other hemoblobinopathies. The development of oral chelators has not 
changed this position. However this has not settled the controversy on how this curative but 
potentially  lethal  treatment  stands  in  front  of  medical  therapy  for  adults  and  advanced 
rently  is  reserved almost Medit J Hemat Infect Dis 2009, 1, Open Journal System 
exclusively  for  patients  with  clinical  features  that  indicate  a  poor  outcome  or  significant 
sickle-related morbidity.
Introduction: In easy words the rationale basis of 
allogeneic  hemopoietic  stem  cell  (HSC) 
transplantation  in  thalassemia  consists  in  sub-
stituting  the  ineffective  thalassemic  erythropoiesis 
with and allogeneic effective one
1. This approach is 
an efficient way to obtain a long lasting, probably 
permanent,  clinical  effective  correction  of  the 
haemolytic  anaemia
1.  Thus avoiding  transfusion 
requirement and subsequent complications like iron 
overload.  Allogeneic  hemopoietic  stem  cell 
transplantation  in  genetic  disease  has  been  a 
cornerstone  of  the  development  of  HSC 
transplantation
2 and  a  topic  of  passionate  debate 
during the past decades
3,4. Although transplantation 
role  in  thalassemia  is  today  well  established  this 
debate would be more important today in the oral 
chelator era and in the era of a worldwide diffuse 
medicine with increasing attention to the problem of 
the costs.  
HSC transplantation in a not malignant disease: 
The  issue  of  HSC  transplant  in  hemo-
globinopathies is conceptually more similar to solid 
organ  transplantation  than  to  HSC  transplant  in 
haematological malignancies. In this setting there is 
not  a  malignant  clone  to  eradicate  and  a  Graft 
versus  Leukemia effect is  not  required.    On  the 
other  hand  there  is  not  a  malignant  progressive 
disease  to  be  included  in  the  risk/benefit  ratio 
analyses.  Patients  have  not  received  previous 
chemotherapy  and  immunosuppression  but  have 
erythroid expansion and iron-related tissue damage. 
This  cellular  replacement  therapy  has  been 
improperly defined “gene therapy today”.
All  these  findings  must  be  considered  in 
patients’ selection and transplant execution.
Figure 1. Results of HSC transplantation in 900 consecutive 
patients, ager 1-35 years, transplanted from an HLA identical 
sibling in Pesaro since December 1981. 
Results  of  transplantation:  The  first  HSC 
transplant for thalassemia was performed in Seattle 
on  Dec  2, 1981
5.  Subsequently  between  17 
December 1981 and 31 January 2003, over  1000 
consecutive  patients,  aged  from  1  to  35  years, 
underwent  transplantation  in  Pesaro.  In  fig  1  is 
reported  the  thalassemia  free  survival  obtained  in 
900 consecutive patients transplanted from an HLA 
identical sibling.  Overall, the greater than 20-year 
Kaplan–Meier  probability  of  thalassemia-free 
survival was 73% (Figure 1)
6.
With regard to predictors of transplant outcome, 
in the historical experience, patients younger than 
17  years  were  stratified  on  the  basis  of  the  risk 
factors  of  hepatomegaly,  a  history  of  irregular 
chelation,  and  hepatic  fibrosis
7.  With  the 
combination  of  oral  Busulfan  14  mg/kg  and 
Cyclophosphamide 200  mg/kg  as  preparative 
regimen results were satisfactory for patients with 
no  advanced  disease (Class 1  and  Class 2)  while 
were  unacceptable  for  patients  with  advanced 
disease  (Class  3)
7.  For  the  first  two  category  of 
patients  this  conditioning regimen  has  remained 
unmodified  since  1985
8.    For  the  discouraging 
results  with  this  conditioning  regimen  in  patients 
with advanced disease, after 1990 class 3 patients 
underwent  transplantation based  on  protocols  that 
included lower dosages of cyclophosphamide (120–
160  mgkg)
9.  Transplantation  in  class  3  children, 
with this regimen was characterized by a 30% risk 
of  thalassemia  recurrence
9.  In  contrast,  in  adults 
with  the  same  dose  of  cyclophosphamide, 
thalassemia recurrence was only 4%, but there was 
a  35%  transplant-related  mortality
10.  These 
historical Pesaro results are reported in Table 1.
Because  class  3  children  had  the  problem  of 
thalassemia  recurrence  whereas  adults  had  the 
problem  of  transplant-related  mortality  a  new 
preparative  regimen  was  introduced  for  class  3 
patients  with  the  aim  of  increasing  the  rate  of 
sustained engraftment while decreasing transplant-
related  mortality.  This  regimen  was  characterized 
by  a  30-day  preconditioning  period  designed  to 
produce  erythroid  cytoreduction  and  immune-
suppression before a conditioning regimen using a 
reduced dose of cyclophosphamide. In a pilot study 
of 33 consecutive class 3 thalassemia children, the 
5-year  Kaplan–Meier  probability  of  survival  and 
disease  free  survival  was  93%  and  85%, 
respectively
11. Medit J Hemat Infect Dis 2009, 1, Open Journal System 
Table 1. Results of transplantation. Historical results from Pesaro experience during the eighties and nineties.
Regimen Overall Survival Thalassemia Free Survival
Class 1 Bu 14 – Cy 200 93 % 90%
Class 2 Bu 14 – Cy 200 87% 84%
Class 3 Bu 14 – Cy 120 -160 79% 58%
Adults Bu 14 – Cy 120 -160 66% 62%
Application of transplantation world-wide: After 
have  been  pioneered  by  the  Seattle  group
5,  the 
Pesaro  group
4,7,8,12-15 and  the  Pescara  group
16 this 
therapeutic  approach  is  now  widely  applied 
worldwide
6.  In  the  early  eighties  transplantation 
procedure  was  limited  to  very  few  centres 
worldwide.  The  European  Group  for  Blood  and 
Marrow Transplantation has recently established the 
hemoglobinopathy registry and it is possible today 
to a have detailed epidemiology data on over 3,000 
patients registered. After the early ninety a constant 
numbers of transplants raging between 133 and 197 
per  year  have  been  registered  with  a  constant 
behaviour  during  the  years  (Figure  2)
6.    The 
pioneering role of the Pesaro group is today clear 
(Figure  3)  and  the  wide  dissemination  of  this 
practice after 1993 is the best demonstration of its 
success. 
Transplantation versus medical therapy: Medical 
therapy  of  thalassemia  is  one  of  the  most 
spectacular successes of the medical practice in the 
last  decades.  Thalassemia  has  been  transformed 
from an infant lethal disease in a chronic disease 
permitting  prolonged  survival.  An  Italian  retro-
spective  study
17 clearly  demonstrated  which  has 
been the medical progress in this setting comparing 
survival  of  patients  born  in  different  decades. 
Nevertheless  situation  is  dramatically  different  in 
non-industrialized  countries  were  the  very  large 
majority of patients live today.
In recent years advances in knowledge of iron 
overload patho-physiopathology, improvement and 
diffusion of diagnostic capability together with the 
development  of  new  effective  and  safe  oral 
chelators
18,19 promise to further increase success of 
medical  therapy
20.  Particularly  today  well-studied 
oral  chelators  offer  a  concrete  alternative  to 
deferoxamine infusion therapy.
The  problem  of  the  choice  between 
transplantation versus medical therapy is a kind of 
question,  which  cannot  be  resolved,  for  several, 
obvious,  reasons  by  a  prospective  randomized 
clinical  trial.  In  absence  of  such  data  the  choice 
should  be  done  on  analyses  of  large  prospective 
(transplant)  and  retrospective  (medical  therapy) 
phase II trials and individual preference. In this kind 
of clinical question several aspects must be kept in 
Figure 2. Numbers of HSC transplants performed for thalassemia in centers of the European Registry for Blood and Marrow 
Transplantation (EBMT). Unpublished data from the EBMT Hemoglobinopathy RegistryMedit J Hemat Infect Dis 2009, 1, Open Journal System 
Figure 3. Numbers of HSC transplants performed for thalassemia through the years in centres of the European Registry for Blood 
and Marrow Transplantation (EBMT). The blue bars indicate transplants performed in Pesaro. The yellow bars indicate transplants 
performed in all the other centres. Unpublished data from the EBMT Hemoglobinopathy Registry
consideration  making  the  decisional  process 
different  in  individual  cases:  age,  clinical  status, 
capability  and  compliance  to  adhere  a  correct 
transfusional-chelation regimen  and  resources.  In 
case of children the dilemma dramatically relies on 
parents shoulders. 
Resources  availability:  Even  if  not  properly 
medical  issue  resources  availability  is  a 
fundamental issue. A modern complete transfusion 
– chelation  therapy  is  a  high  technology  therapy 
requiring important expertise. Even not considering 
complication,  medical  therapy  is  very  expensive 
clearly  not  widely  available  worldwide
21.    Even 
transplantation is a high technology therapy but the 
diffusion of transplant centres is greatly increased 
today
22.  It  has  been  calculated  that  in  term  of 
resources  availability  and  utilization  HSC 
transplantation  corresponds  to  approximately  3 
years  of  transfusion- chelation  therapy  with 
deferoxamine not including complications costs.
In large part of the world, were today lives the 
large  part  of  thalassemia  patients,  the  choice 
between  transplant  and  medical  therapy  cannot 
consider  just  reported  literature  but  resources 
availability also.
Alternative  source  of  stem  cells:  The  large 
majority  of  transplant  in  thalassemia  has  been 
performed using bone marrow derived stem cells. In 
the EBMT survey more than 80% of the transplants 
have  been  performed  using  bone  marrow  derided 
cells. Even in the most recent years, although less 
pronounced,  bone  marrow  derived  stem  cells 
continue to be the preferred source of stem cells for 
transplantation in thalassemia. 
In 1998 Franco Locatelli first proposed the use 
of identical sibling derived hemopoietic stem cells 
for transplantation in hemoglobinopathies
27.  Since 
that time  use  of  cord  blood  derived  hemopoietic 
stem  cell  has  much  expanded
28 with  outstanding 
results  in  the  field  of  hemo-globinopathies 
particularly regards a very low mortality rate.
Alternative  donor:  As  very  well  known  in 
transplantation only  approximately  1/3  of patients 
has  an  HLA  identical  sibling  inside  the  family
23. 
Use  of  alternative  donors  includes  matched 
unrelated  donor,  mismatched  donors.  The  first 
approach has been applied by a multicentre Italian 
study  and  demonstrated  satisfactory  results
24. 
However the  limited number of  cases  reported (<
100  in  more than  10  years) and  the  limitation in 
donor selection makes this procedure be reserved to 
specialized centres and controlled trials.  
Unrelated cord blood transplantation is standard 
practice  today  for  HSC  therapy  in  malignancies. 
Tolerance  of  1-2  HLA  antigens  mismatch,  fast 
availability and low incidence of graft versus host 
disease  makes  this  option  very  attractive  for  not Medit J Hemat Infect Dis 2009, 1, Open Journal System 
malignant  diseases  including  thalassemia. 
Preliminary experience is promising but limited (36 
reported cases with a 77% overall survival and 65% 
thalassemia  free  survival)
25 and,  therefore,  should 
be  considered  a  experimental  approach.   
Mismatched donor transplantation has been issue of 
a  very  limited  number  of  trials
26.  Because  of  the 
experimental role  of  this  procedure  and  the 
alternative of medical therapy available today this 
procedure  should  be  not  recommended  unless  in 
very  selected  clinical  cases lacking  an  HLA 
compatible donor  in which medical therapy  has 
been formally documented to be not feasible.
Alternative  conditioning  regimens:  Be-cause  of 
the lack of a malignant clone to eradicate and the 
need to reduce toxicity non-ablative transplantation 
would have theoretically a role in thalassemia and 
hemoglobinopathies.  However  attempts  performed 
in this direction failed.  This was recently reported 
in  two  limited  experiences
29,30.  Overall  eleven 
patients  with  Thalassemia  or  Sickle  cell  Disease 
received a non-myeloablative regimen before HSC 
transplant. As expected transplant related mortality 
was  very  limited  but  only  one  patient  had  a 
sustained  engraftment.  This  was  probably  due  to 
expanded  erythroid  clone  and  the  immunological 
situation  demonstrating  that  a  stable  allogeneic 
engraftment  is  difficult  to  obtain  in 
hemoglobinopathies  and  additional immunological 
tools would be necessary. However in the setting of 
a  not-malignant  disease  the  addiction  of  post 
transplant  donor  lymphocyte  infusion  does  not 
appears  to  a  rational approach  in  terms  of 
risk/benefit ratio.
Mixed  chimerism:  In  the  setting  of  HSC 
transplantation mixed chimerism is defined as the 
concurrent presence of donor and host hemopoietic 
cells.  Mixed chimerism is commonly reported after 
HSC  transplant  for  thalassemia  after  a  myelo-
ablative-conditioning  regimen.  In  a  prospective 
study  by  Andreani  in  over  300  consecutive 
thalassemia patients
31 early mixed chimerism was 
demonstrated in 28% of the patients. Of them only 
approximately  one  fourth  (11%  of  the  surviving 
patients)  confirmed  mixed  chimerism  in  a 
prolonged follow up extending over the second year 
after transplant (persistent chimerism). In a recent 
study  from  Pavia  this  behaviour  has  not  been 
confirmed  in  the  setting  of  cord  blood 
transplantation
28.
Very interesting and surprising in those patients 
who presented persistent mixed chimerism a partial 
engraftment, up to the 20% of marrow cells, was 
still  able  to  maintain  a  normal  hemoglobin  level 
avoiding blood transfusions. In this population, no 
sign  of  increasing  iron  overload  or  other  clinical 
complication  of  thalassemia  or  thalassemia 
intermedia  were  detectable,  thus  obtaining  a 
complete clinical control of the disease. 
Regardless of mechanism correction of anemia 
by  relatively  low  amount  of  mixed  chimerism  
provide  the  rationale  for  development  of 
minimally–ablative conditioning regimens to obtain 
a partial engraftment and at the same time abolish 
or drastically decrease transplant related mortality. 
The evidence that a partial engraftment of a normal 
erythropoiesis    provide  clinical  control  of  the 
disease could also be the basis for a gene therapy 
program (when  safely available) since eradication 
of  the  thalassemic  marrow  is  not  necessary  to 
clinical control of the disease.
Transplantation  for  thalassemia  in  the  era  of 
oral  chelators:  The  central  role  of  HSC  in 
thalassemia  has  now  been  fully  established. 
Transplantation remains the only definitive curative 
therapy  for  thalassemia  and  other  hemoglobino-
pathies. The development of oral chelators has not 
changed this position. However this has not settled 
the controversy on how this curative but potentially 
lethal treatment stands in front of medical therapy 
for  adults  and  advanced  disease  patients.    Trans-
plantation technologies have improved substantially 
during the last years and transplantation outcome is 
likely  to  be  much  better  today  than  in  the  ‘80s. 
Recent  data  indicated  a  probability  of  overall 
survival and thalassemia free survival of 97% and 
89% for patients with no advanced disease and of 
87% and 80% for patients with advanced disease 
32. 
Similar data are coming from the EBMT survey on 
over  1000  patients  transplanted  in  the  EBMT 
centres during the last 10 years with a over 90% 
overall survival at 5 years. 
Transplantation for Sickle Cell Disease: Similar 
to  β  thalassemia  major,  the  objective  of  HSC 
transplantation for sickle cell disease is to substitute 
recipient  erythropoiesis,  or  to  reduce  its  clinical 
impact, by the expression of donor β-globin chains. 
The clinical benefit of this cellular replacement is 
the elimination, or noteworthy amelioration, of the 
clinical complications caused by polymerized sickle 
hemoglobin. Since the initial clinical trials of HSC 
transplantation for sickle cell disease it  was clear 
that  the  replacement  of  donor  for  sickle 
erythropoiesis  might  abolish  not  only  the Medit J Hemat Infect Dis 2009, 1, Open Journal System 
hematological  manifestations  of  the  underlying 
disorder,  but  also  stabilize and  even  decrease the 
organ damage caused by previous recurrent vessel 
occlusion  and  haemolysis
33-36.  As  in  thalassemia 
there  is  usefulness  in  assigning  a  risk-based 
approach to applying transplantation for sickle cell 
disease. Unfortunately, defining risk characteristics 
is  difficult  in  the  absence  of  prospective  trials. 
Nonetheless, the appropriate broader application of 
HSC  transplantation  hinges  on  two  important 
objectives. 
1. To  identify  those  patients  who  have  the 
greatest  risk  of  developing  sickle-related 
complications  and  who  are  most  likely  to 
benefit  from  hematopoietic  cell 
transplantation. 
2. To reduce transplant-related complications by 
minimizing  the  short- and  long-term 
toxicities of HSC transplantation.
Unlike β-thalassemia major, where the genotype 
directs a reasonably reliable phenotype in the vast 
majority of cases, the clinical expression of sickle 
cell anemia is quite variable and difficult to predict 
based upon the hemoglobin genotype alone. Thus, 
in standard practice, HSC transplantation for sickle 
cell disease currently is reserved almost exclusively 
for  patients  with  clinical  features  that  indicate  a 
poor  outcome  or  significant  sickle-related 
morbidity,  in  part  due  to  the  toxicity  of  this 
intensive therapy
37. These clinical indications are 
listed in Table 2. 
Table 2. Indications of Hematopoietic Cell Transplantation for 
Sickle Cell Disease
One or more of the following complications: 
 Stroke or central nervous system event lasting > 24h.
 Impaired neuropsychological function with abnormal 
cerebral MRI and angiography
 Recurrent acute chest syndrome
 Stage I or II sickle lung disease
 Recurrent  vaso-occlusive  painful  episodes  or 
recurrent priapism
 Sickle nephropathy (glomerular filtration rate 30% -
50% of predicted normal values)
Other indications to be considered:
 Abnormal  transcranial  Doppler,  pulmonary 
hypertension, silent cerebral infarction.
These criteria have been developed and applied 
almost exclusively on children, for whom the risk–
benefit ratio is most advantageous in terms of years-
of-life  gained.  Less  certain  is  how  to  apply 
inclusion criteria to adults with sickle cell anemia, 
in  whom the  experience  of  transplantation  is 
limited,  but  for  whom  the  risk  of  significant 
transplantation-related toxicity remains substantial. 
For  all  patients,  clinicians  must  carefully  weigh 
therapeutic alternatives to hematopoietic cell trans-
plantation,  with  particular  attention  to  safety, 
efficacy, availability, and the cost of intervention
38-
40.
The  worldwide  experience  of  conventional 
myeloablative hematopoietic cell transplantation for 
sickle cell disease
34-36,41-44 is summarized in Table 
3.  In the  collective experiences of these  studies, 
HSC transplantation moved  from an  experimental 
intervention reserved for severely affected patients, 
to one in which younger children with early signs of 
sickle-related morbidity are included.  The results 
of  transplantation  were  best  when  performed  in 
children  with  sickle  cell  disease  who  had  HLA-
identical  sibling  donors.    Even  though  many 
children  who  received  allografts  had  significant 
sickle-related  complications  such  as  stroke  and 
recurrent  episodes  of  acute  chest  syndrome,  the 
disease-free  survival  rate  was  80%  to  85%  quite 
similar in the different experiences; however, 5%–
10%  of  patients  died  of  complications  related  to 
transplantation, with  GVHD  and  its treatment  the 
leading cause of death
As  in  thalassemia  major,  the  observation  of 
donor–host  hematopoietic  chimerism  after 
conventional  myeloablative  hematopoietic  cell 
transplantation  has  lent  substantial  support  to  the 
notion that persistence of even a fraction of normal 
engrafted  erythropoiesis  might  elicit  a  curative 
clinical  effect
31,44 leading  to  the  same  potentiality 
for  a  gene  therapy  approach  as  described  for 
thalassemia.
Conclusion: HSC  transplantation  in 
hemoglobinopathies has  today  a  well-recognized 
place  as  therapeutic  option  for  these  inherited 
diseases.  As  elsewhere  described  in  this  journal, 
these  diseases  have  a  tremendous  impact  with 
hundred of thousands of patients (mostly children) 
affected  worldwide  of  whom  few  have  the 
transplant option. As above described the transplant 
decision  is  much  different  in  the  two  diseases 
requiring deep knowledge of the diseases and at the 
same  time  of  the  transplant  possibility  and 
limitation.    Any  effort  should  be  done  to  further 
decrease transplant related mortality and to extend 
transplantation option to patients so far lacking an 
HLA identical donor and to those without modern 
healthcare resources. Medit J Hemat Infect Dis 2009, 1, Open Journal System 
Table 3: worldwide results obtained by Myeloablative HSC transplantation in Sickle Cell Disease.
US Collaborative French Belgian CIBMTR
Patients 59 87 50 67
Median age 9.9 (3.3 – 15.9) 9.5 (2-22) 7.5 (0.9 – 23) 10 (2-27)
Disease Recurrence. 8.5% 8% 10% 13%
Deaths 7% 7% 4% 4.5%
Event Free survival 85% 85% 86% 82%
Patients with Chronic GvHD 12% 12.6% 20% 22%
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